NCT01922583View on ClinicalTrials.gov

AUY922 in Patient With Stage IV NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
DRUG

AUY922

AUY922 will be administered via IV over 1 hour once weekly in a 21 day cycle until disease progression

Trial Locations (3)

100

Department of Oncology, National Taiwan University Hospital, Taipei

11217

Taipei Veterans General Hospital, Taipei

70403

National Cheng Kung University Hospital, Tainan City

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER

NCT01922583 - AUY922 in Patient With Stage IV NSCLC | Biotech Hunter | Biotech Hunter